DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for extraosseous osteosarcoma — screening already-approved drugs against its 28-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleExtraosseous osteosarcoma maps to a 28-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for extraosseous osteosarcoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
neurotrophic receptor tyrosine kinase 3 (NTRK3) — NTRK3 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 4-aminophenyldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 6KZD · 1.708 Å · ligand 3-[2-[6-(4-aminophenyl)imidazo[1,2-a]pyrazin-3-yl]ethynyl]-2-methyl-~{N}-[3-(4-methylpiperazin-1-yl)-5-propan-2-yl-phenyl]benzamide (DZ6). Experimental structure, not a prediction.
What the evidence adds up to
Extraosseous osteosarcoma is a very rare malignant neoplasm, with about 300 cases published by 2006. Manifestation within the thyroid gland had been described in only 6 cases by that year. A 2006 report describes a 69-year-old woman with a high-grade extraosseous osteosarcoma of the thyroid presenting as an enlarged recurrent struma five years after primary resection and radiotherapy. A 2024 case report describes a 57-year-old man with a 9.5 cm extraosseous osteosarcoma in the left rectus femoris muscle, diagnosed by MRI and pathology. The interdisciplinary tumour board recommended neoadjuvant systemic therapy, surgical resection, postoperative systemic therapy, and discussion of adjuvant radiotherapy.
A 1980 clinical analysis of ten cases reports an overall five-year survival rate of 42.9%. That same analysis states that en bloc excision is the treatment of choice and that amputation should be reserved for large tumours with major neurovascular involvement or unresectable recurrence. The 2024 report concludes that extraosseous osteosarcoma should be treated as an aggressive soft tissue sarcoma and that multimodality treatment should be actively sought to improve outcome.
No randomised trials or prospective studies are available for this disease. What is missing is prospective data from adequately sized, multicentre trials that can test specific chemotherapy regimens and radiotherapy protocols, as well as reliable biomarkers for patient stratification. The rarity of the tumour makes such trials difficult to fund and complete.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Laryngo-Rhino-Otologie · 2006 · 8 citations
Extraossäres Osteosarkom der Schilddrüse
AbstractExtraosseous osteosarcomas are very rare malignant neoplasms that have been published in 300 cases so far. Manifestation within the thyroid gland was described in 6 cases only. We report a 69 year old female who suffered from enlarged recurrent struma after primary resection and radiotherapy 5 years ago. Histology revealed a high grade extraosseous osteosarcoma. Presenting the patient's clinical, radiological and histological findings the therapeutical options of this rare tumor entity are discussed.
EXTRAOSSEOUS OSTEOGENIC SARCOMA: A CLINICAL ANALYSIS OF TEN CASES
AbstractThis article describes the clinical manifestations, roentgenographic appearance, microscopic features and short- and long-term prognosis of ten cases of extraosseous osteosarcoma. The surgical technique of wedge biopsy and en bloc excision with interlocking sutures has also been illustrated. We feel that en bloc excision is the treatment of choice, and that amputation should be reserved for large tumors with major neurovascular involvement and unresectable recurrence. The overall five-year survival rate was 42.9%.
Journal of Radiology Case Reports · 2024 · 0 citations · open access
A Rare Case of Primary Extraosseous Osteosarcoma (EOS) of the thigh: A Case Report
AbstractBackground: Extraosseous osteosarcoma (EOO) is a rare mesenchymal malignancy, which produces osteoid, bone, or chondroid material and is located in the soft tissue without attachment to skeletal bones. Case presentation: A 57-year-old male patient presented with extraosseous osteosarcoma located in the left rectus femoris muscle. The external magnetic resonance imaging revealed a large, irregular non-homogeneous contrast enhanced mass (largest diameter 9.5 cm). The final pathological diagnosis yielded extraosseous osteosarcoma. After interdisciplinary tumor board discussion, the following procedure was recommended: neoadjuvant systemic therapy with subsequent resection of the tumor and postoperative continuation of systemic therapy as well as discussion of adjuvant radiotherapy.Conclusion: EOO should be treated as a soft tissue sarcoma with aggressive behavior and multimodality treatment should be actively sought to improve treatment outcome.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
